The Radiopharmaceutical Therapy for Multiple Bone Metastases of Cancer.
10.14475/kjhpc.2014.17.4.207
- Author:
Sang Gyu CHOI
1
Author Information
1. Department of Radiation Oncology, Dankook University College of Medicine, Cheonan, Korea. am2ran@gmail.com
- Publication Type:Review
- Keywords:
Neoplasm metastasis;
Radiopharmaceuticals;
Radiation oncology
- MeSH:
Analgesics;
Breast;
Breast Neoplasms;
Carcinoma, Renal Cell;
Drug Therapy;
Lung Neoplasms;
Motor Activity;
Neoplasm Metastasis*;
Osteoblasts;
Palliative Care;
Pathology;
Prostatic Neoplasms;
Quality of Life;
Radiation Oncology;
Radiopharmaceuticals;
Radiotherapy;
Weight-Bearing
- From:Korean Journal of Hospice and Palliative Care
2014;17(4):207-215
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Multiple bone metastases are common manifestation of many malignant tumors such as lung cancer, breast cancer, prostate cancer and renal cell carcinoma. Bone metastasis is secondary cancer in the bone, and it can lead to bone pain, fracture, and instability of the weight bearing bones, all of which may profoundly reduce physical activity and life quality. Treatment for bone metastasis is determined by multiple factors including pathology, performance status, involved site, and neurologic status. Treatment strategies for bone metastasis are analgesics, surgery, chemotherapy and radiotherapy. External beam radiotherapy has traditionally been an effective palliative treatment for localized painful bone metastasis. However, in some cases such as multiple bone metastases, especially osteoblastic bone metastasis originated from breast or prostate cancer, the radiopharmaceutical therapy using (89)Sr, (186)Re, (188)Re, (153)Sm and (117m)Sn are also useful treatment option because of administrative simplicity (injection), few side effects, low risk of radiation exposure and high response rate. This article offers a concise explanation of the radiopharmaceutical therapy for multiple bone metastases.
